Member Info for LewSur

Per SoloCheck.ie: Conroy Gold and Natural Resources Public Limited Company was set up on Wednesday the 19th of April 1995.

Sorry to say the number shares held is likely to be one hundredth of what it was.

23 November 2015

CAPITAL REORGANISATION AND CONSOLIDATION

Conroy Gold and Natural Resources plc (AIM: CGNR, ESM: CGNR.I), the gold exploration and development company focused on Ireland and Finland, announces a proposed capital reorganisation of its share capital ('Capital Reorganisation').

The Capital Reorganisation comprises firstly a subdivision of the Existing Ordinary Shares (and also the unissued but authorised Ordinary Shares) and secondly a consolidation of the subdivided Ordinary Shares to create the New Ordinary Shares. The effect of the Capital Reorganisation is to reduce the number of Ordinary Shares in issue by a multiple of approximately 100.

Prof,
Looking for downside risks, it might be helpful to know what contingency planning there is for the awful possibility of losing for any reason the services of the wonderful Leon. Who stands behind him ?

https://www.mining.com/web/copper-the-most-critical-metal/

Thanks. Perhaps my original question was disingenuous, but it would be good to know whether this explanation of the wild disparities sometimes seen on this site is always or usually the explanation and whether this means that the values shown in the portfolio summaries are more reliable than those detailed for individual stocks. I check elsewhere when I really want to know and I suppose the only definitely reliable information comes from trying to trade, but I like the premise here of showing at a glance how good or bad a day one is having and of course the opportunity of reading the valuable (or rubbish!) comments in the chat. In the present case the only trade showing today is an A trade for £3.10 value!

Can anybody explain for me what the entries on this website mean? Currently my Zioc holding is shown in my portfolios having lost £3245 today while in this tab Zioc is shown as being 5.08% up with only one trade at 6.20 characterised as a sale.

20 Dec is a Sunday. Payment date is actually 18 Dec.

Thanks, JLPp. Hope you have quashed that suggestion on the SLP board. Market clearly far from troubled.

And squirt it up their noses!

Anybody have a view on whether this mooted tax would be material to JLP as has been suggested elsewhere?
https://www.engineeringnews.co.za/article/chrome-export-tax-a-positive-step-special-electricity-dispensation-now-needed-steve-phiri-2020-11-16/rep_id:4136

Sounds great: will they sell it?

· Jubilee nearly doubles its access to secured copper and cobalt tailings to reach an approximate 270 million tonnes

· The Agreements secure the rights to an additional approximate 115 million tonnes of copper containing tailings located within a 50 km radius from Jubilee's Project Elephant and within the Kitwe area

· The additional Tailings offer the potential to double the targeted production profile for Project Elephant estimated at 12 000 tonnes of copper units per annum in addition to Project Roan, currently under construction

· The close proximity of all of the projects offers the potential to integrate components of the processing facilities, which could offer significant capital savings

· The Agreements places Jubilee on track to deliver its objective of reaching 25 000 tonnes of copper units per annum

· This implementation of these Agreements combined with Jubilee's existing copper projects, will establish Jubilee as a leading copper producer from historical tailings alone

· The Tailings have been previously drilled and sampled to confirm both content and size containing on average 0.3% copper and 0.05% cobalt

· The combined magnitude of the total secured copper tailings resources and related projects, together with Jubilee's Sable Refinery, offers the potential to deliver long term sustained quality earnings making a significant contribution to Jubilee's existing earnings from its PGM and chrome operations in South Africa

· The Sable Refinery is operationally ready and able to significantly enhance its capacity alongside the expected production build up, without incurring any significant new capital expenditure

400k in a SIPP and 1100k in an ISA.

Time to fess up that my first tranche of shares cost me 30.16p each a month short of ten years ago. I wouldn't mind seeing that price again! Many additions since then, lowest at 1.64p in2015.

Follow the instructions in the RNS of the 16th and you can watch a recording of the presentation.

Was the planning consent for up to 1000 dwellings mentioned in the RNS already factored into the share price?

US LiquiBand®

We are pleased to report that end market sales data for LiquiBand® show that it has started to recover some momentum which resulted in strong sales volumes for the first quarter of 2020 and market share gains. This strong performance predated the significant reduction in demand seen since the start of the second quarter as a result of the COVID-19 pandemic but did evidence that the sales initiatives implemented in late 2019 and earlier this year have been successful. In addition to this, the launch of LiquiBand® Rapid™ went ahead with one of the Group’s main US partners, albeit at a lower level than originally planned due to COVID-19 restrictions. This partner is now well positioned to compete in the US market when hospitals reopen for elective surgery.



The LiquiBand® XL critical pilot study has been completed with three different formulations successfully meeting our objective of 14-day wear time. However, some of the variants demonstrated extended set time. The lead formulation, which we believe maximises our potential for long term commercial success on all product features, is an accelerated formulation of LiquiBand® that will require additional stability and biocompatibility data along with a repeat of the clinical study as part of the FDA filing. The additional work required on this lead formulation means that we now expect to file for 510K approval in the first quarter of 2021. We expect the financial impact of this delayed approval to be offset by the stronger than anticipated LiquiBand® market share improvement and short term commercial agreements with US hospitals to encourage additional LiquiBand® adoption in the run up to the LiquiBand® XL approval. Once approved, LiquiBand® XL will allow entry into the market for care of larger wounds and unlock further growth potential in the LiquiBand® business with all partners.





Chris Meredith, Chief Executive Officer of AMS, commented: “Our strong balance sheet enables us to weather the disruption of COVID-19 whilst continuing to invest in R&D and regulatory projects, in order to be in the best position to return to strong growth when the Group’s end markets recover to a more normal basis.



Given the strong demand for LiquiBand® in the first quarter, the launch of LiquiBand® Rapid™ and the development plan now in place for LiquiBand® XL that will allow entry into the larger wounds market, we remain confident in the growth potential for the LiquiBand® portfolio.”



The Group expects to release a trading update covering the first six months of the financial year in early July 2020.



– End –

The Group confirms it is in robust financial condition to weather the continued global disruption caused by the pandemic and retains its strong cash balances broadly in line with its position at 31 December 2019 (£65 million and no debt) with an undrawn unsecured £80 million credit facility, which is committed until December 2023.



As announced at the start of April, the Group was experiencing a slowdown in demand for its products caused by the cancellation or postponement of elective surgeries, dental procedures and a reduction in the volume of accident & emergency treatments. There has also been a slow-down in hospital treatment of chronic wounds and some supply disruption due to the global lockdowns. As a result, the Group has been experiencing reductions to its revenues at the upper end of the 3% to 5% of annual sales per month estimate announced by the Board in April.



Although we are anticipating a gradual return to more normalised levels of hospital activity for both our surgical and woundcare businesses, the Group expects the effects of COVID-19 will continue to have an impact in the second half of 2020, albeit at a lower level, as volumes will take time to recover to pre-COVID-19 levels.



As previously stated, the Group continues to manage its operating costs, working capital and capital expenditure to ensure that it remains in the strongest possible financial and operational position to return to strong growth when the Group’s end markets recover. Reflecting the ongoing financial strength of the Group and the Board’s belief in the long-term prospects of AMS, the Board reconfirms its intention to recommend the payment of the proposed final dividend for 2019.

How much larger than 34% can it get?

Apparently ignored and unloved. Why?